NASDAQ$NKTX

Nkarta Inc · Q1 2026 earnings

Q1 2026 earnings · · Investor relations

Briefing

Nkarta reported Q1 2026 with no product revenue, net loss of $27.8M, and diluted loss per share of $0.37.

For the period ended 2026-03-31, Nkarta reported no product revenue. Pre-revenue; R&D $25.0M. Net loss $27.8M. Clinical-stage; no product guidance. Funding from cash and equity.

  • Pre-revenue; R&D $25.0M.
  • Net loss $27.8M.
  • No revenue.

Headline financials

Total Revenue

$0.00

Previous: $0.00
EPS (adj)

-$0.37

Previous: -$0.43+14.0%
Capital Expenditures

-$413K

Previous: -$518K+20.3%
Free Cash Flow

-$28.6M

No prior period
Net Income

-$27.8M

Previous: -$32M+13.0%
Operating Income

-$30.9M

Previous: -$36.6M+15.6%
Gross Profit

$0.00

No prior period
Cash & Equivalents

$27.4M

No prior period
Total Assets

$372M

No prior period

Revenue & EPS history

Nkarta · Revenue · Quarterly

$0

Q1 2026

Forward guidance

Clinical-stage; no product guidance. Funding from cash and equity.

Tailwinds

  • R&D focused on NK cell therapies.
  • Lower loss vs. prior year.

Headwinds

  • No revenue.
  • Clinical trial and financing risk.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 18 quarterly earnings reports · overlaid with Q1 2026

Historical avgQ1 2026

+0.9%

Avg return

Earnings day

-2.2%

Avg return

5 days after

-0.9%

Avg return

30 days after

63%

15 / 24 earnings

Positive

+16.2%

Q4 2021

Best reaction

-30.3%

Q4 2023

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q4 2025+0.9%-14.8%
Q1 2026+3.5%-16.1%-13.2%
Q3 2025+3.1%-4.6%-4.6%
Q2 2025+12.8%+19.9%+0.5%
Q1 2025+1.2%-0.6%-4.6%
Q4 2024+3.2%-15.4%+13.3%
Q3 2024-4.8%-9.0%-23.0%
Q2 2024+1.2%+0.0%+10.3%
Q1 2024-2.3%+2.3%+3.1%
Q4 2023-30.3%-22.8%-43.0%
Q3 2023-5.6%+7.0%+27.0%
Q2 2023-0.5%-1.0%-20.5%
Q1 2023-4.1%-4.1%-0.9%
Q4 2022+1.3%-7.1%+19.3%
Q3 2022-8.4%-2.1%-35.5%
Q2 2022+8.8%+11.1%-8.5%
Q1 2022+12.8%+11.1%+6.9%
Q4 2021+16.2%+6.2%-15.2%
Q3 2021+7.7%+7.2%-15.0%
Q2 2021-1.9%-5.0%-29.0%
Q4 2020+0.0%-14.4%-30.3%
Q3 2020+2.9%+14.5%+122.0%
Q2 2020-7.0%-12.0%+21.1%
Q1 2021+11.3%
Q4 2019
Q3 2019
Q2 2019
Q1 2019

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro